D-allulose maintained weight loss more persistently than oral semaglutide in obese mice — both reduced food intake and improved grip strength, but semaglutide's effects rebounded after stopping while D-allulose's persisted.
Weight maintained vs reboundedD-allulose maintained weight loss after treatment cessation while oral semaglutide's effect diminished and rebounded — potentially due to D-allulose engaging both vagal and central pathways
What the researchers found
In diet-induced obese mice under identical conditions:
- Acute effects: D-allulose rapidly reduced feeding; oral semaglutide reduced it more slowly
- Days 0-3: both profoundly reduced food intake and body weight equally
- Days 4-10: weight loss diminished with oral semaglutide but was maintained with D-allulose
- After treatment cessation: weight rebounded with semaglutide but was maintained with D-allulose
- Both increased muscle grip strength equally
- Mechanism: both activated anorexigenic (appetite-suppressing) leptin-responsive neurons in the hypothalamus, but only D-allulose significantly inhibited orexigenic (appetite-stimulating) ghrelin-responsive neurons
- D-allulose works via both vagal afferent and central nervous routes; semaglutide mainly via central route
Why it matters
Weight regain after stopping GLP-1 drugs is a major clinical concern — most patients regain weight when they stop semaglutide. If D-allulose can maintain weight loss more sustainably (even if these are mouse results), it could complement or provide an alternative to expensive injectable drugs. The dual-pathway mechanism may explain why the effects are more durable.
How the study worked
Diet-induced obese mice received D-allulose or oral semaglutide under identical conditions: equivalent doses, oral gavage, and matched food/water deprivation. Acute food intake was measured, followed by sub-chronic assessment of food intake, body weight, and grip strength over 10 days. Hypothalamic neuron responses were studied to elucidate mechanistic differences between the two treatments.
What this study cannot tell us
This was a short-term mouse study (10 days) that may not predict long-term human outcomes. D-allulose and oral semaglutide dosing equivalence in mice may not translate to human dosing. The oral gavage delivery method doesn't reflect normal eating behavior. Mouse appetite regulation differs from humans in important ways. The grip strength finding is preliminary and needs further investigation.
How to read the evidence
This is a short-term preclinical mouse study comparing two interventions under controlled conditions. While it provides interesting mechanistic insights, the results cannot be directly extrapolated to human obesity treatment.
When this study was published
Published in 2026, this is very recent research addressing the critical clinical question of weight rebound after GLP-1 drug cessation.
The bigger picture
Weight rebound after GLP-1 drug cessation is one of the biggest challenges in obesity treatment, with studies showing patients regain most lost weight within a year of stopping. This study suggests that approaches stimulating endogenous GLP-1 release (like D-allulose) might provide more durable effects than direct receptor agonism, potentially through engaging additional gut-brain signaling pathways.
Questions still open
- Would combining D-allulose with semaglutide provide more durable weight loss than either alone?
- Do D-allulose's dual-pathway effects translate to more sustained weight loss in human clinical trials?
- Could D-allulose be used as a transition strategy when patients are tapering off GLP-1 drugs?
Common questions
What is D-allulose?
Could D-allulose replace semaglutide for weight loss?
Read the original research
D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.
Nutrients, 18(4)
Citation
Rakhat, Yermek; Banno, Seiya; Zhantleu, Dauren; Tsunekawa, Shin; Yabe, Daisuke; Seino, Yutaka; Iwasaki, Yusaku; Yada, Toshihiko. (2026). D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.. Nutrients, 18(4). https://doi.org/10.3390/nu18040707